Aprea Therapeutics（APRE）株式概要アプレア・セラピューティクス社は臨床段階にあるバイオ医薬品会社で、DNA損傷応答経路を標的とする新規合成致死ベースの癌治療薬の開発・商業化に注力している。 詳細APRE ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6報酬過去5年間の収益は年間42.6%増加しました。 リスク分析意味のある時価総額がありません ( $9M )収益が 100 万ドル未満 ( $286K )過去1年間で株主の希薄化は大幅に進んだ US市場と比較した過去 3 か月間の株価の変動+1 さらなるリスクすべてのリスクチェックを見るAPRE Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.82182.1% 割高 内在価値ディスカウントEst. Revenue$PastFuture-113m4m2016201920222025202620282031Revenue US$3.6mEarnings US$618.7kAdvancedSet Fair ValueView all narrativesUNCYFeaturedLooking to be second time lucky with a game-changing new productKey Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.View narrativeSTstuart_robertsCommunity ContributorUS$21.53FV • 64.4% 割安 内在価値ディスカウント5419.8%Revenue growth p.a.Set Fair Value6.2k1801283mo agoAprea Therapeutics, Inc. 競合他社CytoMed TherapeuticsSymbol: NasdaqCM:GDTCMarket cap: US$11.5mSunshine BiopharmaSymbol: NasdaqCM:SBFMMarket cap: US$5.2mXenetic BiosciencesSymbol: NasdaqCM:XBIOMarket cap: US$6.8mbioAffinity TechnologiesSymbol: NasdaqCM:BIAFMarket cap: US$9.8m価格と性能株価の高値、安値、推移の概要Aprea Therapeutics過去の株価現在の株価US$0.8252週高値US$2.2252週安値US$0.55ベータ1.571ヶ月の変化14.34%3ヶ月変化8.95%1年変化-55.78%3年間の変化-79.03%5年間の変化n/aIPOからの変化-93.96%最新ニュースAprea Therapeutics, Inc., Annual General Meeting, Jun 16, 2026Apr 21Aprea Therapeutics, Inc. announced that it has received $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management LlcApr 01Aprea Therapeutics, Inc. announced that it expects to receive $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc and other investorsMar 31Aprea Therapeutics Announces Positive Emerging Clinical Activity for Wee1 Inhibitor Apr-1051 with Confirmed Partial Response in Ongoing Phase 1 Acesot-1051 TrialMar 30Full year 2025 earnings: EPS exceeds analyst expectations Mar 18New major risk - Shareholder dilution Mar 17最新情報をもっと見るRecent updatesAprea Therapeutics, Inc., Annual General Meeting, Jun 16, 2026Apr 21Aprea Therapeutics, Inc. announced that it has received $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management LlcApr 01Aprea Therapeutics, Inc. announced that it expects to receive $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc and other investorsMar 31Aprea Therapeutics Announces Positive Emerging Clinical Activity for Wee1 Inhibitor Apr-1051 with Confirmed Partial Response in Ongoing Phase 1 Acesot-1051 TrialMar 30Full year 2025 earnings: EPS exceeds analyst expectations Mar 18New major risk - Shareholder dilution Mar 17No longer forecast to breakeven Mar 16Aprea Therapeutics, Inc. Announces Additional Positive Clinical Activity for WEE1 Inhibitor, Apr-1051, Including Second Partial Response in Ongoing ACESOT-1051 TrialFeb 18Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline GrowthFeb 12New minor risk - Profitability Feb 09Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical AdvisorFeb 04New minor risk - Share price stability Jan 31Aprea Therapeutics, Inc. announced that it expects to receive $5.597083 million in fundingJan 30Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing Acesot-1051 Dose-Escalation Trial Evaluating Wee1 Inhibitor Apr-1051, Including Partial Response Observed on First ScanJan 29Aprea Therapeutics, Inc. Receives Notice of Nasdaq Deficiency Due to Sustained Low Stock PriceJan 25No longer forecast to breakeven Dec 23Aprea Therapeutics, Inc. announced that it expects to receive $3.055822 million in fundingDec 09New minor risk - Shareholder dilution Nov 17Forecast to breakeven in 2027 Nov 17Third quarter 2025 earnings released: US$0.47 loss per share (vs US$0.64 loss in 3Q 2024) Nov 14Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination TherapiesOct 16New major risk - Revenue size Aug 13Second quarter 2025 earnings released: US$0.53 loss per share (vs US$0.58 loss in 2Q 2024) Aug 13New minor risk - Share price stability Jul 22Aprea Therapeutics, Inc. Announces New Preclinical Data and A Clinical Update on Apr-1051Jun 25Insufficient new directors Jun 01First quarter 2025 earnings released: US$0.66 loss per share (vs US$0.67 loss in 1Q 2024) May 15Aprea Therapeutics, Inc., Annual General Meeting, Jun 05, 2025Apr 24Price target decreased by 8.9% to US$13.67 Apr 04Aprea Therapeutics, Inc. Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 TrialMar 31Aprea Therapeutics, Inc. Auditor Raises 'Going Concern' DoubtMar 27Full year 2024 earnings: EPS and revenues exceed analyst expectations Mar 25Consensus revenue estimates increase by 21% Jan 17New major risk - Shareholder dilution Jan 16Aprea Therapeutics, Inc. Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potential Optimize Clinical Outcomes and Strengthen Clinical Path ForwardDec 12Aprea Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.Nov 09Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 08Consensus revenue estimates increase by 49% Oct 27Aprea Therapeutics, Inc. Presents Preliminary Findings on Oral WEE1 Inhibitor Apr-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and TherapeuticsOct 23Independent Director recently bought US$132k worth of stock Oct 18Nadeem Mirza to Step Down as Chief Medical Officer of Aprea Therapeutics, IncOct 09Consensus revenue estimates increase by 92%, EPS downgraded Aug 19New major risk - Revenue and earnings growth Aug 13Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans?Aug 06Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051Jun 18Aprea Therapeutics, Inc. Announces Safety Review Committee Endorses Dosing of Patients with ATRN-119 at 800 Mg Once Daily in Ongoing ABOYA-119 Clinical TrialMay 29Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza as Chief Medical OfficerMay 03Aprea Therapeutics, Inc., Annual General Meeting, Jun 20, 2024Apr 27New minor risk - Shareholder dilution Mar 27Aprea Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $2 million.Mar 26Consensus revenue estimates increase by 39% Mar 20Aprea Therapeutics Receives FDA Approval of the IND Application for the Drug Candidate Apr-1051Mar 16Aprea Therapeutics, Inc. Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing CancersMar 13Aprea Therapeutics, Inc. announced that it expects to receive $16.000005 million in funding from Exome Asset Management LLC, Stonepine Capital Management LLC, Nantahala Capital Management, LLC, Dafna Capital Management, LLC and other company insidersMar 12New major risk - Share price stability Mar 08Aprea Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1 million.Jan 26We're Keeping An Eye On Aprea Therapeutics' (NASDAQ:APRE) Cash Burn RateJan 10Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024Jan 05Consensus revenue estimates decrease by 34%, EPS upgraded Nov 16Aprea Therapeutics, Inc. Announces Preclinical Data Supporting Highly Differentiated Wee1 Inhibitor, Atrn-1051, Reliable to Other Wee1 InhibitorsSep 12Aprea Therapeutics, Inc. Announces Board ChangesAug 25New major risk - Revenue and earnings growth Aug 11New minor risk - Share price stability Aug 04Aprea Therapeutics, Inc., Annual General Meeting, Aug 23, 2023Jul 12Aprea Therapeutics, Inc. Appoints Gabriela Gruia to Board of DirectorsMay 09High number of new directors Apr 01Aprea Therapeutics, Inc. Announces Management ChangesJan 31+ 1 more updateAprea Therapeutics, Inc. Doses First Patient in Phase 1/2A Clinical Trial of Oral ATN Inhibitor ATRN-119 for the Treatment of Advanced Solid TumorsJan 12Aprea Therapeutics Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price RequirementSep 17Aprea Therapeutics, Inc. Receives a Deficiency Letter, from the Listing Qualifications Department of the Nasdaq Stock MarketAug 20Aprea Therapeutics, Inc. Elects John B. Henneman III and Christian S. Schade as DirectorsAug 03Aprea Therapeutics, Inc., Annual General Meeting, Jul 28, 2022Jun 11No independent directors May 18Atrin Pharmaceuticals Inc. Announces Management ChangesMay 18+ 2 more updates株主還元APREUS BiotechsUS 市場7D-12.0%-2.4%0.8%1Y-55.8%27.4%27.8%株主還元を見る業界別リターン: APRE過去 1 年間で27.4 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: APREは、過去 1 年間で27.8 % のリターンを上げたUS市場を下回りました。価格変動Is APRE's price volatile compared to industry and market?APRE volatilityAPRE Average Weekly Movement15.2%Biotechs Industry Average Movement10.8%Market Average Movement7.1%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: APREの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: APREの weekly volatility ( 15% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a8Oren Giladaprea.comアプレア・セラピューティクス社は臨床段階にあるバイオ医薬品会社で、DNA損傷応答経路を標的とする新規合成致死ベースの癌治療薬の開発・商業化に注力している。同社の主要製品候補は、バイオマーカーを有する進行固形癌患者を対象に第1相臨床試験中の経口生物学的利用可能な低分子WEE1キナーゼ阻害剤APR-1051と、固形癌を対象に第1/2a相臨床試験中のATR阻害剤ATRN-119である。本社はペンシルバニア州ドイルタウン。もっと見るAprea Therapeutics, Inc. 基礎のまとめAprea Therapeutics の収益と売上を時価総額と比較するとどうか。APRE 基礎統計学時価総額US$9.37m収益（TTM）-US$12.60m売上高(TTM)US$285.76k32.8xP/Sレシオ-0.7xPER（株価収益率APRE は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計APRE 損益計算書（TTM）収益US$285.76k売上原価US$7.04m売上総利益-US$6.76mその他の費用US$5.84m収益-US$12.60m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-1.10グロス・マージン-2,364.68%純利益率-4,409.16%有利子負債／自己資本比率0%APRE の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 06:50終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aprea Therapeutics, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Esther Lannie HongBerenbergJoseph PantginisH.C. Wainwright & Co.Jason McCarthyMaxim Group1 その他のアナリストを表示
UNCYFeaturedLooking to be second time lucky with a game-changing new productKey Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.View narrativeSTstuart_robertsCommunity ContributorUS$21.53FV • 64.4% 割安 内在価値ディスカウント5419.8%Revenue growth p.a.Set Fair Value6.2k1801283mo ago
Aprea Therapeutics, Inc. announced that it has received $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management LlcApr 01
Aprea Therapeutics, Inc. announced that it expects to receive $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc and other investorsMar 31
Aprea Therapeutics Announces Positive Emerging Clinical Activity for Wee1 Inhibitor Apr-1051 with Confirmed Partial Response in Ongoing Phase 1 Acesot-1051 TrialMar 30
Aprea Therapeutics, Inc. announced that it has received $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management LlcApr 01
Aprea Therapeutics, Inc. announced that it expects to receive $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc and other investorsMar 31
Aprea Therapeutics Announces Positive Emerging Clinical Activity for Wee1 Inhibitor Apr-1051 with Confirmed Partial Response in Ongoing Phase 1 Acesot-1051 TrialMar 30
Aprea Therapeutics, Inc. Announces Additional Positive Clinical Activity for WEE1 Inhibitor, Apr-1051, Including Second Partial Response in Ongoing ACESOT-1051 TrialFeb 18
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline GrowthFeb 12
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing Acesot-1051 Dose-Escalation Trial Evaluating Wee1 Inhibitor Apr-1051, Including Partial Response Observed on First ScanJan 29
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination TherapiesOct 16
Aprea Therapeutics, Inc. Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 TrialMar 31
Aprea Therapeutics, Inc. Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potential Optimize Clinical Outcomes and Strengthen Clinical Path ForwardDec 12
Aprea Therapeutics, Inc. Presents Preliminary Findings on Oral WEE1 Inhibitor Apr-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and TherapeuticsOct 23
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051Jun 18
Aprea Therapeutics, Inc. Announces Safety Review Committee Endorses Dosing of Patients with ATRN-119 at 800 Mg Once Daily in Ongoing ABOYA-119 Clinical TrialMay 29
Aprea Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $2 million.Mar 26
Aprea Therapeutics Receives FDA Approval of the IND Application for the Drug Candidate Apr-1051Mar 16
Aprea Therapeutics, Inc. Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing CancersMar 13
Aprea Therapeutics, Inc. announced that it expects to receive $16.000005 million in funding from Exome Asset Management LLC, Stonepine Capital Management LLC, Nantahala Capital Management, LLC, Dafna Capital Management, LLC and other company insidersMar 12
Aprea Therapeutics, Inc. Announces Preclinical Data Supporting Highly Differentiated Wee1 Inhibitor, Atrn-1051, Reliable to Other Wee1 InhibitorsSep 12
Aprea Therapeutics, Inc. Doses First Patient in Phase 1/2A Clinical Trial of Oral ATN Inhibitor ATRN-119 for the Treatment of Advanced Solid TumorsJan 12
Aprea Therapeutics Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price RequirementSep 17
Aprea Therapeutics, Inc. Receives a Deficiency Letter, from the Listing Qualifications Department of the Nasdaq Stock MarketAug 20
